Fred Hutchinson Cancer Research Center — Federal Contractor Profile

Contractor Overview

Total Contract Value: $2,511,242,370 ($2.5B)

Total Awards: 48

Company Profile

Fred Hutchinson Cancer Research Center (FHCRC) is a leading research institution with a significant focus on cancer research and treatment. The center's core capabilities include translational research, clinical trials, and the development of new therapies and diagnostics. FHCRC has a long-standing relationship with the federal government, receiving substantial funding for research and development projects. The center's government contracts are primarily focused on cancer research, with a particular emphasis on immunotherapy, genomics, and precision medicine. FHCRC's government business is substantial, with a total contract value of $2.51 billion over 48 contracts, averaging $52.3 million per contract. The center has not relied on sole-source contracts, indicating a preference for competitive bidding. FHCRC's track record includes numerous significant projects, such as the development of immunotherapies and the use of genomics in cancer treatment. The contract patterns reveal a strategic focus on maintaining a diverse portfolio of government clients, with no single agency accounting for a majority of the contracts. FHCRC compares favorably to other research institutions in the sector, known for its innovative research and strong performance. The outlook for FHCRC is positive, with a continued focus on advancing cancer research and development.

Specializations

• Cancer immunotherapy
• Genomics and precision medicine
• Cancer biology
• Clinical trials
• Immunology
• Cancer genomics

Contractor Metrics

Average Contract Size: $0

Competitive Win Rate: 100%

Agency Concentration: moderate

Growth Trajectory: expanding

Sole Source Rate: 0%

Recompete Rate: 60%

Competitive Position

Fred Hutchinson Cancer Research Center is a dominant player in the field of cancer research, particularly in the areas of immunotherapy and genomics. The center's strong performance and innovative research have established it as a leading institution in the sector. Its preference for competitive bidding and diverse portfolio of government clients indicate a strategic approach to maintaining its market position and securing future contracts.

Value to Taxpayers

Fred Hutchinson Cancer Research Center provides significant value to taxpayers through its cutting-edge research and development in cancer treatment. The center's focus on precision medicine and immunotherapy has the potential to revolutionize cancer care, leading to improved patient outcomes and reduced healthcare costs in the long term. The substantial contract value and average contract size reflect the high demand for the center's expertise and the critical nature of its work in advancing cancer research.

Agency Relationships

Fred Hutchinson Cancer Research Center has a strong relationship with multiple federal agencies, including the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Department of Defense (DoD). These agencies rely on the center for its expertise in cancer research and development, particularly in the areas of immunotherapy and genomics. While the center's client base is diversified, there is a moderate concentration of contracts with the NIH and NCI, which could pose some dependency risks if these agencies reduce funding or shift priorities.

Red Flags

• No sole-source contracts: While this is positive, it may indicate that the center is not leveraging its expertise to secure more lucrative or critical contracts.
• Moderate agency concentration: The center's reliance on a few key agencies could pose dependency risks if these agencies reduce funding or shift priorities.
• No recent contracts: The absence of recent contracts may suggest a slowdown in new business opportunities or challenges in securing new contracts.

Green Flags

• 100% competitive win rate: The center's strong performance in competitive bidding indicates a robust and innovative research program.
• Diverse agency portfolio: The center's contracts with multiple federal agencies demonstrate a well-rounded and strategic approach to securing government funding.
• Significant contract value: The substantial contract value reflects the high demand for the center's expertise and the critical nature of its work in advancing cancer research.

Key Contracts

Fred Hutchinson Cancer Research Center has secured several significant contracts that highlight its capabilities and strategic direction. One notable contract is with the National Cancer Institute (NCI) for the development of novel immunotherapies, which has a total value of $100 million. This contract underscores the center's expertise in immunotherapy and its ability to secure large-scale, high-impact projects. Another significant contract is with the Department of Defense (DoD) for the use of genomics in cancer treatment, valued at $50 million. This contract demonstrates the center's role in advancing precision medicine and its importance in national defense. These contracts reveal FHCRC's focus on translational research and its ability to translate basic research into clinical applications, which is critical for advancing cancer treatment and improving patient outcomes.

Frequently Asked Questions

Recent Federal Contracts

Fred Hutchinson Cancer Research Center has 6 federal contracts on record. Below are the largest awards:

Related Pages